{"SPADE_N_03150": {"Clinical Information": [], "Patent Information": [{"Patent No": "US 2003/0092612 A1", "Patent Link": "http://www.lens.org/lens/patent/US_2003_0092612_A1", "Patent Type": "Patent Application", "Publication Date": "2003-5-15", "Family Info": "CA2451469A1,EP1406647A1,EP1406647A4,US6872705,WO2003006046A1", "Patent Title": "Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions.", "Abstract": "Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially non-oxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention."}, {"Patent No": "US 6872705 B2", "Patent Link": "http://www.lens.org/lens/patent/US_6872705_B2", "Patent Type": "Granted Patent", "Publication Date": "2005-3-29", "Family Info": "US4525346,US6372234,US6482799", "Patent Title": "Use Of Antimicrobial Peptides As Preservatives In Ophthalmic Preparations, Including Solutions, Emulsions, And Suspensions", "Abstract": "Methods for preserving ophthalmic compositions are disclosed. In one embodiment, such compositions include a liquid medium and an antimicrobial component which is preferably substantially nonoxidative. Compositions which include a liquid medium and antimicrobial peptide magainins, present in an amount effective as a preservative, are also disclosed. Preserved compositions useful for administering a therapeutic component to the eyes or caring for contact lenses are also included within the scope of the present invention."}], "Sequence Information": {"SPADE ID": "SPADE_N_03150", "Peptide Name": "Neutrophil defensin 3 (Defensin, alpha 3; HNP-3, HP-3, HP3; Human, mammals, animals)", "Source": "Homo sapiens (Human)", "Family": "Belongs to the alpha-defensin family", "Gene": "DEFA3", "Sequence": "DCYCRIPACIAGERRYGTCIYQGRLWAFCC", "Sequence Length": 30, "UniProt Entry": ["http://www.uniprot.org/uniprot/P59666", "http://www.uniprot.org/uniprot/P11479", "http://www.uniprot.org/uniprot/Q14125"], "Protein Existence": "Protein level", "Biological Activity": ["Antimicrobial", "Antibacterial", "Anti-Gram+", "Anti-Gram-", "Antifungal", "Antiviral(SARS-CoV-2)"], "Target Organism": "[Ref.34206990]Virus:SARS-CoV-2:inhibition of infection in HEK293T-hACE2 cells(approximately 50% inbibition at 1 μg/mL (290 nM)).Gram-negative bacteria:Escherichia coli ATCC 8739 (vLD50=6.2±0.9 µg/ml), E. coli ATCC 25922 (vLD50=5.9±2.1 µg/ml), Enterobacter aerogenes ATCC 13048 (vLD50=41±9.2 µg/ml);Gram-positive bacteria:Staphylococcus aureus ATCC 25923 (vLD50=13±2.1 µg/ml), S. aureus ATCC 29213 (vLD50=2.2±0.4 µg/ml), Bacillus cereus ATCC 10876 (vLD50=0.37±0.08 µg/ml).(Ref.2)NOTE:vLD50, virtual lethal doses (vLDs), equivalent to conventional 50% lethal doses (LD50s).", "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry", "Cytotoxicity": "No cytotoxicity information found in the reference(s) presented", "Binding Target": "Not found", "Linear/Cyclic": "Cyclic", "N-terminal Modification": "Free", "C-terminal Modification": "Cyclization(Cys2 and Cys30).", "Stereochemistry": "L", "Structure Description": "Compared to HNP-2, HNP-3 contains one additional residue (Asp) at the N-terminus. The 3D structures remain the same.", "Formula": "C151H228N44O40S6", "Mass": 3492.09, "PI": 8.33, "Net Charge": 2, "Hydrophobicity": 0.12, "Half Life": "Mammalian:1.1 hourYeast:3 minE.coli:>10 hour", "Function": "Defensin 3 have antibiotic, fungicide and antiviral activities. Has antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma membrane.", "PTM": "Contains three disulfide bonds 2-30; 4-19; 9-29.", "Literature": [{"Title": "Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry.", "Pubmed ID": "34206990", "Reference": "Viruses. 2021 Jun 26;13(7)1246.", "Author": "Xu C, Wang A, Marin M, Honnen W, Ramasamy S, Porter E, Subbian S, Pinter A, Melikyan GB, Lu W, Chang TL.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=34206990"}, {"Title": "Primary structures of three human neutrophil defensins.", "Pubmed ID": "4056036", "Reference": "J Clin Invest. 1985 Oct;76(4)1436-1439.", "Author": "Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=4056036"}, {"Title": "Antibacterial activity and specificity of the six human {alpha}-defensins.", "Pubmed ID": "15616305", "Reference": "Antimicrob Agents Chemother. 2005 Jan;49(1)269-275.", "Author": "Ericksen B, Wu Z, Lu W, Lehrer RI.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=15616305"}], "Frequent Amino Acids": "CRA", "Absent Amino Acids": "HKMNOSUV", "Basic Residues": 4, "Acidic Residues": 2, "Hydrophobic Residues": 13, "Polar Residues": 18, "Positive Residues": 4, "Negative Residues": 2, "Similar Sequences": [{"SPADE_ID": "SPADE_N_03110", "Similarity": 1.0, "Sequence": "DIPEVVVSLAWDESLAPKHPGSRKNMDCYCRIPACIAGERRYGTCIYQGRLWAFCC"}, {"SPADE_ID": "SPADE_N_03149", "Similarity": 1.0, "Sequence": "CYCRIPACIAGERRYGTCIYQGRLWAFCC"}, {"SPADE_ID": "SPADE_UN_07691", "Similarity": 1.0, "Sequence": "CYCRIPACIAGERRY"}]}}}